Gain Therapeutics Reports Positive Results from Phase 1 Study of GT-02287, Showcasing Promising Safety and Tolerability Profile

Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...

April 25, 2024 | Thursday | News
DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

    -DoseMe, a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Au...

April 17, 2024 | Wednesday | News
FibroBiologics Secures Australian Patent for Breakthrough Cartilage Regeneration Method

FibroBiologics, , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...

April 12, 2024 | Friday | News
Australian Biotech Firm Ferronova Initiates Clinical Trial for FerroTrace® Nanoparticle Technology in Gastric and Oesophageal Cancers

Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in pat...

April 10, 2024 | Wednesday | News
Align Technology Launches Invisalign® Palatal Expander System in Australia and New Zealand

Invisalign® Palatal Expanders offer doctors an effective and easily removable alternative to traditional palatal expanders, without the need for meta...

April 02, 2024 | Tuesday | News
Australia's Telix Pharmaceuticals Forges Alliance to Drive Personalized Cancer Treatment

Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic agreement to partner with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaf...

March 19, 2024 | Tuesday | News
Fennec and Norgine Partner to Commercialize PEDMARQSI in Europe, Australia, and NZ

Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...

March 18, 2024 | Monday | News
Biocon Biologics and Sandoz Australia Forge Partnership for Biosimilars Trastuzumab and Bevacizumab

Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...

February 09, 2024 | Friday | News
MaxCyte and Imugene Forge Strategic License for Cancer Immunotherapy Advancement

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, de...

January 23, 2024 | Tuesday | News
ClinChoice Expands Global Presence with Acquisition of CSI in Southeast Asia

ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around t...

January 15, 2024 | Monday | News
First patient has been dosed in Clarity's Phase III trial for Cu-64 SAR-bisPSMA in prostate cancer in Australia

First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial, CLARIFY. The aim of the CLARIFY trial is to detect regional nodal...

December 27, 2023 | Wednesday | News
BrainStorm Secures Patents for Allogeneic Exosome Platform in Neurological Disorders

The European Patent office granted patent No. 3105587 titled 'Method of Qualifying of Cells' for a method of qualifying whether a cell population is a suit...

December 27, 2023 | Wednesday | News
Carina Biotech Doses First Australian Patient in LGR5 CAR-T Trial

First patient dosed in Australia where 3 clinical trial sites have been activated. The trial will enrol advanced colorectal cancer patients whose cancer...

December 19, 2023 | Tuesday | News
Parse Biosciences Secures $50M for Global Growth

Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...

December 18, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close